RDU Webinar Series: Precision Cancer Medicine: Focus on Children

Recorded On: 02/15/2017

Oncologists heave been personalizing patient care for many years. When oncologists review slides with a pathologist to arrive at an accurate diagnosis or review radiology scans to determine stage in order to determine the most appropriate treatment regimen, they are personalizing patient care. The significant advances that have occurred in gene sequencing technologies and the development of new more targeted drugs has allowed oncologists to personalize care even more by matching gene alterations (mutations, copy number alterations and translocations) found in an individuals own tumor to targeted therapies. The term precision cancer medicine is now used most often used to refer to this type of care. Dr. Katherine Janeway is pediatric hematologist-oncologist and researcher with joint appointments at Harvard Medical School, Dana-Farber Cancer Institute, and Children’s Hospital, Boston.  She is the Director of the Pediatric Solid Tumor Program, a member of the Dana-Farber/Harvard Cancer Center Genetics Program and leader of the Pediatric Oncology Precision Cancer Medicine Initiative. This presentation will provide an overview of the advances in genomics and targeted therapy that make precision cancer medicine possible and will review the research being conducted in Precision Cancer Medicine with a focus on clinical sequencing studies, basket trials and pediatric oncology.

Katherine Janeway, MD, MMSc

Dr. Katherine Janeway is  a pediatric hematologist-oncologist and researcher with joint appointments at Harvard Medical School, Dana-Farber Cancer Institute, and Children’s Hospital, Boston.  She is the Director of the Pediatric Solid Tumor Program, a member of the Dana-Farber/Harvard Cancer Center Genetics Program and leader of the Pediatric Oncology Precision Cancer Medicine Initiative. 

Key:

Complete
Failed
Available
Locked